TOP TEN perturbations for 39703_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39703_at
Selected probe(set): 203992_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39703_at (203992_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.3275423Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.0782604Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.9197016Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
actinomycin D study 1 / mannitol treated A549 cell sample
Relative Expression (log2-ratio):-2.9036627Number of Samples:3 / 3
Experimental | actinomycin D study 1 |
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code: | |
Control | mannitol treated A549 cell sample |
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.804408Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.634694Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-2.4290009Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
oncolytic herpes simplex virus study 1 / mock infected peripheral nerve sheath tumor (90-8) cell sample
Relative Expression (log2-ratio):2.3956375Number of Samples:2 / 2
Experimental | oncolytic herpes simplex virus study 1 |
Human malignant peripheral nerve sheath tumor (90-8) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (90-8) cell sample |
Human malignant peripheral nerve sheath tumor (90-8) cells mock infected for 6 hours. |
esophagus cancer study 1 (PDX; adenocarcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.3040686Number of Samples:2 / 8
Experimental | esophagus cancer study 1 (PDX; adenocarcinoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
Control | esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted). |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):2.204424Number of Samples:2 / 7
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary. |